TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03191981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Treatment for all patients will be with cyclophosphamide, lenalidomide and pembrolizumab at fixed doses.
Study: NCT04648566

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Intrauterine administration of sperm washing medium
Description: Administration of sperm washing medium instead of PBMC in the uterine cavity of the patient
Study: NCT03569150

Intervention type: OTHER
Group type: OTHER
Intervention: Cultural adaptation/implementation COMFORT CC
Description: The COMFORT Communication Curriculum (CC) will be culturally-adapted for 2 Native American reservation communities. The investigators will then implement the culturally-adapted COMFORT Communication Curriculum in 2 tribal communities by training interdisciplinary healthcare professionals to conduct culturally-respectful and relevant Advance Care Planning. The investigators will then conduct a cluster-assigned pilot, wait-list controlled trial of the culturally-adapted COMFORT Communication Curriculum in 2 tribal communities to evaluate feasibility, acceptability, and perceived effectiveness by comparing 30 Native Americans completing Advance Care Planning with a trained healthcare professional and 30 Native Americans receiving usual care.
Study: NCT02018926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mocetinostat
Description: Mocetinostat (a histone deacetylase \[HDAC\] inhibitor) 70 mg or 90 mg dose, oral capsules 3 times weekly beginning on day 5, for 10 doses in each 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine (a hypomethylating agent \[HMA\]) 75 mg/m2 dose, by intravenous (IV) infusion or subcutaneous (SC) injection beginning on day 1 for 7 doses in each 28 day cycle
Study: NCT04514965

Intervention type: OTHER
Intervention: Blood sampling
Description: Blood sampling

Intervention type: DEVICE
Intervention: Fibroscan
Description: Measurement of liver stiffness

Intervention type: OTHER
Intervention: Question
Description: Question about pruritus
Study: NCT01792219

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interprofessional collaboration in health care module
Description: An educational module
Study: NCT03752944

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: lefort I osteotomy for maxillary advancement
Description: fixation of lefort I osteotomy in patients with retruded maxilla with two prebent plates versus four miniplates.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lefort I osteotomy for maxillary advancement
Description: fixation of lefort I osteotomy in patients with retruded maxilla with two prebent plates versus four miniplates.
Study: NCT03230500

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computer guided implant placement
Description: Implant will be placed immediately using computer aided surgical guide

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computer guided implant placement
Description: Implant will be placed immediately using computer aided surgical guide
Study: NCT03054558

Intervention type: OTHER
Intervention: Pelvic ultrasound both two dimensional and three dimentional

Intervention type: OTHER
Intervention: Pelvic ultrasound both two dimensional and three dimentional
Study: NCT03911050

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Apple consumption
Description: Apple blends (600 g) One single dose

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: Breakfast without any apple-related products
Study: NCT02926820

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cogmed QM
Description: The intervention consisted of 25 Cogmed sessions, typically completed over a five week period (i.e. 5 days per week), with each session lasting between 40-50 minutes per day. The program consists of 12 exercises that target visuo-spatial or verbal working memory. At each training session, participants completed 8 of the 12 exercises (order selected by the user), with 15 trials per exercise. Cogmed QM is an adaptive program, wherein task difficulty is adjusted to performance on each trial. The level of difficulty adjusts continuously and automatically, ensuring that each session provides an engaging, challenging level of WM capacity. Breaks were permitted, and encouraged, at the participants' discretion throughout the session.
Study: NCT05623943

Intervention type: PROCEDURE
Intervention: Endovascular treatment
Description: Patients treated with endovascular treatment, including balloon angioplasty alone and balloon angioplasty plus stenting.
Study: NCT04155307

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anal EndoFLIP®
Description: Anal EndoFLIP® measure to evaluate anal compliance

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Anal Manometry
Description: Anal Manometry done in standard care

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Defecography
Description: Defecographydone in standard care

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Electromyogram
Description: Electromyogram done in standard care
Study: NCT01305395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Will initiate sirolimus within 6 months of heart transplant
Study: NCT02051478

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic mobilization
Description: Patients will receive 20 seconds bouts of grade III-IV of central posterior-anterior (PA) non-thrust mobilization from T3 to T6 spinous process as described by Maitland et al for an overall intervention time of approximately 2 minutes
Study: NCT01305395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Will start sirolimus after CAV has been diagnosed by angiogram

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Will start sirolimus after CAV has been diagnosed by intravascular ultrasound

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Will start sirolimus after they develop CAV by angiogram

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Will start sirolimus after CAV has been diagnosed by intravascular ultrasound
Study: NCT02494609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sotagliflozin
Description: 400 mg sotagliflozin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral contraceptive
Description: 0.25 mg norgestimate/0.035 mg ethinyl estradiol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral contraceptive + sotagliflozin
Description: 0.25 mg norgestimate/0.035 mg ethinyl estradiol + 400 mg sotagliflozin
Study: NCT02187510

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Umbilical cord milking
Description: Once the preterm is born keep the baby from the mother's thighs. The obstetrician cord milking three times (2seconds/milking) taking the cord from the base 20cm respect towards the baby. Then clamp de cord.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Delayed cord clamping
Description: Once the preterm is born the neonatologist keep the baby beside the mother at level of the operating table during 30 seconds without cord clamping. The baby is covered with a polythene bag and put a cap on his head. Then the obstetritian clamp the cord.
Study: NCT00786994

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oleogel-S10 100 mg/g
Description: topical use once or twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oleogel-S10 100 mg/g
Description: topical use once or twice daily
Study: NCT02051478

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thoracic manipulation
Description: A high-velocity, end range, anterior-posterior thrust applied through the elbows to the mid-thoracic spine will be applied
Study: NCT01239173

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AVLOCARDYL
Description: A grip of 2 tablets of 20 mg each took 90 min before the emotional memory reactivation and the anatomical and functional exploration in fMRI

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A grip of 2 tablets of 20 mg each took 90 min before the emotional memory reactivation and the anatomical and functional exploration in fMRI
Study: NCT00786994

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (petroleum jelly)
Description: topical use once or twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (petroleum jelly)
Description: topical use once or twice daily
Study: NCT01710553

Intervention type: OTHER
Group type: OTHER
Intervention: Glucophage 1000mg
Description: EVALUATE BIOEQUIVALENCE BETWEEN METFORMIN 1000 MG TABLETS MANUFACTURED BY SAVIPHARM J.S.C, VIETNAM AND GLUCOPHAGE® 1000 MG TABLETS MANUFACTURED BY MERCK SANTE S.A.S.2, RUE DU PRESSOIR VERT-45400 SEMOY-FRANCE AND BE REGISTERED IN VIETNAM IN HEALTHY, ADULT, HUMAN MALE SUBJECTS UNDER FASTING CONDITION

Intervention type: OTHER
Group type: OTHER
Intervention: Glucophage 1000mg
Description: EVALUATE BIOEQUIVALENCE BETWEEN METFORMIN 1000 MG TABLETS MANUFACTURED BY SAVIPHARM J.S.C, VIETNAM AND GLUCOPHAGE® 1000 MG TABLETS MANUFACTURED BY MERCK SANTE S.A.S.2, RUE DU PRESSOIR VERT-45400 SEMOY-FRANCE AND BE REGISTERED IN VIETNAM IN HEALTHY, ADULT, HUMAN MALE SUBJECTS UNDER FASTING CONDITION
Study: NCT01239173

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AVLOCARDYL
Description: A grip of 2 tablets of 20 mg each took 90 min before the emotional memory reactivation and the anatomical and functional exploration in fMRI
Study: NCT01710553

Intervention type: OTHER
Group type: OTHER
Intervention: Metformin GSK 1000mg
Description: EVALUATE BIOEQUIVALENCE BETWEEN METFORMIN 1000 MG TABLETS MANUFACTURED BY SAVIPHARM J.S.C, VIETNAM AND GLUCOPHAGE® 1000 MG TABLETS MANUFACTURED BY MERCK SANTE S.A.S.2, RUE DU PRESSOIR VERT-45400 SEMOY-FRANCE AND BE REGISTERED IN VIETNAM IN HEALTHY, ADULT, HUMAN MALE SUBJECTS UNDER FASTING CONDITION

Intervention type: OTHER
Group type: OTHER
Intervention: Metformin GSK 1000mg
Description: EVALUATE BIOEQUIVALENCE BETWEEN METFORMIN 1000 MG TABLETS MANUFACTURED BY SAVIPHARM J.S.C, VIETNAM AND GLUCOPHAGE® 1000 MG TABLETS MANUFACTURED BY MERCK SANTE S.A.S.2, RUE DU PRESSOIR VERT-45400 SEMOY-FRANCE AND BE REGISTERED IN VIETNAM IN HEALTHY, ADULT, HUMAN MALE SUBJECTS UNDER FASTING CONDITION
Study: NCT01453894

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reminder and Outreach Intervention
Description: This intervention includes (1) phone calls and text messages to remind participants that they are due for colorectal cancer (CRC) screening (2) mailed fecal occult blood test (FOBT) to participants so they can perform the test conveniently at home and mail them to the clinic, avoiding the need for a visit (3) plain language information and instructions to support understanding of CRC and FOBT use (4) a CRC screening coordinator to contact those still failing to complete testing by telephone or text (5) a feedback loop to patients regarding test results.
Study: NCT04943978

Intervention type: OTHER
Description: just observational blood and liver sampling
Study: NCT03659461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: oral 100mg Sitagliptin daily will be given for 12 weeks. Subjects are required to undergo OGTT pre and post treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: oral 100mg Sitagliptin daily will be given for 12 weeks. Subjects are required to undergo OGTT pre and post treatment.
Study: NCT00910091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BN83495
Description: BN83495 will be administered as a 40 mg tablet once a day orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Megestrol Acetate (MA)
Description: MA will be administered orally as 160mg daily
Study: NCT02691793

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: sunitinib 37.5mg QD
Study: NCT03518892

Intervention type: DIAGNOSTIC_TEST
Intervention: Resting Metabolic Rate
Description: 30 minute test to determine daily caloric needs

Intervention type: DIAGNOSTIC_TEST
Intervention: Resting Metabolic Rate
Description: 30 minute test to determine daily caloric needs
Study: NCT01239173

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A grip of 2 tablets of 20 mg each took 90 min before the emotional memory reactivation and the anatomical and functional exploration in fMRI
Study: NCT01037998

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: UFUR and Iressa
Description: Iressa 250 mg daily plus UFUR 1# bid
Study: NCT02388880

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ITPR
Description: Single use noninvasive device that is connected to a vacuum source and a means to deliver a positive pressure breath. The device generates negative pressure during the expiratory phase, thus creating subatmospheric intrathoracic pressure between the periods of positive pressure ventilations.
Study: NCT03518892

Intervention type: DIAGNOSTIC_TEST
Intervention: Body Composition
Description: Total Body DXA scan to determine fat mass, fat-free mass, and percent body fat

Intervention type: DIAGNOSTIC_TEST
Intervention: Body Composition
Description: Total Body DXA scan to determine fat mass, fat-free mass, and percent body fat

Intervention type: BEHAVIORAL
Intervention: Dietary Assessment
Description: Self administered dietary logs

Intervention type: BEHAVIORAL
Intervention: Dietary Assessment
Description: Self administered dietary logs
Study: NCT00220987

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive Insulin Therapy
Description: Maintain blood glucose 4.5 - 6.o mmol/L

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Insulin therapy
Description: Maintain blood glucose 8-10mmol/L
Study: NCT00798187

Intervention type: BEHAVIORAL
Intervention: Group Meetings
Description: 10 weekly group meetings lasting 2 hours.

Intervention type: BEHAVIORAL
Intervention: Group Meetings
Description: 10 weekly group meetings lasting 2 hours.

Intervention type: BEHAVIORAL
Intervention: Group Meetings
Description: 10 weekly group meetings lasting 2 hours.

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Surveys

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Surveys

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Surveys
Study: NCT01152788

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rIL-21
Description: 30 μg/kg IV Daily x 5, weeks 1, 3 and 5 every 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dacarbazine
Description: 1000 mg/m2 IV Day 1, every 3 weeks
Study: NCT03191981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Treatment for all patients will be with cyclophosphamide, lenalidomide and pembrolizumab at fixed doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Treatment for all patients will be with cyclophosphamide, lenalidomide and pembrolizumab at fixed doses.
Study: NCT02202772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Description: Intravesical instillation of the Cabazitaxel for 2 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Description: Intravesical instillation of the Cabazitaxel for 2 hours
Study: NCT02701400

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tremelimumab
Description: Given IV
Study: NCT04961931

Intervention type: DRUG
Group type: OTHER
Intervention: Empagliflozin 10 MG
Description: After qualifying for the study all subjects received oral empagliflozin 10 mg once daily for 7 days.

Intervention type: DRUG
Group type: OTHER
Intervention: Empagliflozin 10 MG
Description: After qualifying for the study all subjects received oral empagliflozin 10 mg once daily for 7 days.

Intervention type: DRUG
Group type: OTHER
Intervention: Empagliflozin 10 MG
Description: After qualifying for the study all subjects received oral empagliflozin 10 mg once daily for 7 days.
Study: NCT00934492

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cotrimoxazole dispersible tablet
Description: Cotrimoxazole dispersible tablets 120/240mg daily for six consecutive months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo dispersible tablet
Description: Placebo dispersible tablets 120/240mg daily for six consecutive months.
Study: NCT02202772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Description: Intravesical instillation of the Cabazitaxel for 2 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Description: Intravesical instillation of the Cabazitaxel for 2 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Description: Intravesical instillation of the Cabazitaxel for 2 hours
Study: NCT04524260

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: perioperative painting art therapy (LOM® solution centered art therapy)
Description: We plan to apply painting art therapy as a health-related intervention to patients coming to our department for elective major surgery of the pancreatic and lower gastrointestinal tract for malignant pathologies. Patients will have 3 patient art therapy sessions: one before surgery, one on day 3-5 after surgery during the hospital stay and one during the follow-up 6 weeks postoperative

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: perioperative painting art therapy (LOM® solution centered art therapy) - control
Description: usual care, no particular intervention during the perioperative setting. There will be 2-3 painting art therapy sessions after the follow-up 6 weeks postoperative. Therefore this group is called usual care- or delayed intervention group.
Study: NCT00590967

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT extended field external beam radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT extended field external beam radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Brachytherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Brachytherapy
Study: NCT03229681

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Baduanjin exercise
Description: Participants in this groups received routine rehabilitation training and Baduanjin exercise. During the period of rehabilitation, physicians provides a wide range of medical, nutrition and mental health counseling, as well as rational drug-treatment. Baduanjin exercise protocol according to the Health Qigong Baduanjin Standard enacted by the General Administration of Sports in 2003. Due to the low-activity tolerance of CHF patients, we performed with a refined version of Baduanjin. Each Baduanjin exercise session lasts 45 minutes and continues twice per week for 12 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Routine rehabilitation group
Description: Participants in this qroup only received the routine rehabilitation training. During the period of rehabilitation, physicians provides a wide range of medical, nutrition and mental health counseling, as well as rational drug-treatment. They should also come to rehabilitation center for physical exercise,45 minutes per day，twice per week, lasts 12 weeks.
Study: NCT02933762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54175446
Description: Participants will receive a single oral dose of JNJ-54175446 suspension orally once on Day 1 of part 1 and Day 1 to Day 7 in part 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54175446
Description: Participants will receive a single oral dose of JNJ-54175446 suspension orally once on Day 1 of part 1 and Day 1 to Day 7 in part 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54175446
Description: Participants will receive a single oral dose of JNJ-54175446 suspension orally once on Day 1 of part 1 and Day 1 to Day 7 in part 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54175446
Description: Participants will receive a single oral dose of JNJ-54175446 suspension orally once on Day 1 of part 1 and Day 1 to Day 7 in part 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54175446
Description: Participants will receive a single oral dose of JNJ-54175446 suspension orally once on Day 1 of part 1 and Day 1 to Day 7 in part 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54175446
Description: Participants will receive a single oral dose of JNJ-54175446 suspension orally once on Day 1 of part 1 and Day 1 to Day 7 in part 2.
Study: NCT00590967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Study: NCT02132286

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine XR (extended release)
Description: Treatment of quetiapine XR ( extended release)in MDD patients with S/Lg alleles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine XR (extended release)
Description: Treatment of quetiapine XR ( extended release)in MDD patients with S/Lg alleles
Study: NCT03984773

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nudge
Description: Oncology practices will be randomly assigned to receive an intervention, in which individual clinicians will receive a weekly audit email detailing how many serious illness conversations (SIC) they have had compared to the recommended level, and a link to a list of their patients scheduled in clinic next week at high risk of short-term mortality as identified by a mortality prediction algorithm. Clinicians will have the chance to review the opt-out list and pre-commit to a serious illness conversation with appropriate patients. Clinicians will receive nudge on the day of the patient visit via text message reminding them of their pre-commitment to conduct a serious illness conversation.
Study: NCT02448147

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Interval training
Description: Patients will be submitted to three months aerobic exercise training, three times per week. Each session will have two levels of intensity: one minute at respiratory compensation point heart rate intercalating with two minutes at anaerobic threshold heart rate during thirty minutes.